普纳替尼联合泼尼松一线治疗不适合强化疗的Ph+急性淋巴细胞白血病
INCB84344-201是一项前瞻性多中心2期试验,评估普纳替尼45 mg/d联合泼尼松一线治疗≥60岁或不适合强化化疗及干细胞移植的Ph+ ALL患者。44例患者中24周完全血液学缓解率86.4%,完全分子学缓解率40.9%,中位无事件生存期14.31个月。常见不良事件包括皮疹、乏力、转氨酶升高,心脏及血管不良事件发生率分别为29.5%和27.3%。
要点
- 普纳替尼45 mg/d联合泼尼松在不适合强化疗的Ph+ ALL中24周CHR率86.4%,CMR率40.9%。
- 中位无事件生存期14.31个月,中位总生存期未达到。
- 心脏和血管不良事件发生率较高,分别达29.5%和27.3%,需密切监测。
核心结论
- 普纳替尼联合泼尼松在不适合强化化疗的Ph+ ALL患者中显示出疗效,但较低剂量可能更合适。
研究设计与样本
- 前瞻性、多中心、2期试验(INCB84344-201,原GIMEMA LAL 1811),纳入44例新诊断Ph+ ALL患者,年龄≥60岁或不适合强化化疗及干细胞移植。
主要发现
- 24周完全血液学缓解38/44例(86.4%),完全分子学缓解18/44例(40.9%)。
- 中位无事件生存期14.31个月(95% CI 9.30-22.31),中位总生存期未达到。
- 中位完全血液学缓解持续时间未达到,中位完全分子学缓解持续时间11.6个月。
- 61.4%患者完成核心期。
- 最常见治疗中出现的不良事件为皮疹(36.4%)、乏力(22.7%)、丙氨酸转氨酶升高(15.9%)、红斑(15.9%)和γ-谷氨酰转移酶升高(15.9%)。
关键数值与推荐
- 普纳替尼口服45 mg/d持续48周(核心期),泼尼松从第14-29天逐渐减至60 mg/m2/d。
- 每月预防性鞘内化疗。
- 心脏不良事件发生率29.5%(≥3级18.2%),血管不良事件发生率27.3%(≥3级15.9%)。
- 因不良事件剂量减少、中断和停药的比例分别为43.2%、43.2%和27.3%,5例患者出现致死性不良事件。
临床怎么用
- 对于不适合强化化疗及干细胞移植的Ph+ ALL患者,可考虑普纳替尼联合泼尼松作为一线治疗。
- 治疗期间需密切监测心脏和血管不良事件,并关注皮疹、乏力及肝酶升高等毒性。
- 鉴于毒性较高,在该人群中较低剂量的普纳替尼可能更为合适。
局限性
- 样本量较小(44例),为单臂2期试验。
- 随访时间有限,中位总生存期尚未达到。
- 心脏和血管不良事件发生率较高,需谨慎解读疗效与风险的平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tyrosine kinase inhibitors have improved survival for patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). However, prognosis for old or unfit patients remains poor. In the INCB84344-201 (formerly GIMEMA LAL 1811) prospective, multicenter, phase 2 trial, we tested the efficacy and safety of ponatinib plus prednisone in newly diagnosed patients with Ph+ ALL ≥60 years, or unfit for intensive chemotherapy and stem cell transplantation. Forty-four patients received oral ponatinib 45 mg/d for 48 weeks (core phase), with prednisone tapered to 60 mg/m2/d from days-14-29. Prophylactic intrathecal chemotherapy was administered monthly. Median age was 66.5 years (range, 26-85). The primary endpoint (complete hematologic response [CHR] at 24 weeks) was reached in 38/44 patients (86.4%); complete molecular response (CMR) in 18/44 patients (40.9%) at 24 weeks. 61.4% of patients completed the core phase. As of 24 April 2020, median event-free survival was 14.31 months (95% CI 9.30-22.31). Median overall survival and duration of CHR were not reached; median duration of CMR was 11.6 months. Most common treatment-emergent adverse events (TEAEs) were rash (36.4%), asthenia (22.7%), alanine transaminase increase (15.9%), erythema (15.9%), and γ-glutamyltransferase increase (15.9%). Cardiac and vascular TEAEs occurred in 29.5% (grade ≥3, 18.2%) and 27.3% (grade ≥3, 15.9%), respectively. Dose reductions, interruptions, and discontinuations due to TEAEs occurred in 43.2%, 43.2%, and 27.3% of patients, respectively; 5 patients had fatal TEAEs. Ponatinib and prednisone showed efficacy in unfit patients with Ph+ ALL; however, a lower ponatinib dose may be more appropriate in this population. This trial was registered at www.clinicaltrials.gov as #NCT01641107.
引用
- Martinelli G, Papayannidis C, Piciocchi A, et al. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Adv. 2022. PMID: 34649276. doi:10.1182/bloodadvances.2021004821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。